MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations

Oncotarget

Volumn 8, Issue 15, 2017, Pages 25345-25361

  Cui, Daming ^a   Sajan, Pandey ^a   Shi, Jinlong ^b   Shen, Yiwen ^c   Wang, Ke ^a   Deng, Xianyu ^a   Zhou, Lin ^a   Hu, Pingping ^a   Gao, Liang ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANTONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

GADD45A; Invasion; Migration; MiR 148 ; catenin

Indexed keywords

BETA CATENIN; CELL MARKER; GELATINASE B; ISOCITRATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; MICRORNA; MICRORNA 148A; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; GADD45A PROTEIN, HUMAN; MIRN148 MICRORNA, HUMAN; NUCLEAR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GADD45A GENE; GENE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GLIOBLASTOMA CELL LINE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CASE CONTROL STUDY; CELL MOTION; DOWN REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FEMALE; GLIOMA; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; TRANSFECTION;

EID: 85017569027     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15867     Document Type: Article

References (44)

1. Ohgaki H, Kleihues P. Genetic Pathways to Primary and Secondary Glioblastoma. The American Journal of Pathology. 2007; 170: 1445-53.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica. 2007; 114: 97-109.
3. Purow B, Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol. 2009; 5: 419-26.
4. Hadjipanayis CG, Van Meir EG. Tumor initiating cells in malignant gliomas: biology and implications for therapy. Journal of Molecular Medicine. 2009; 87: 363-74.
5. Chen R, Cohen AL, Colman H. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Curr Treat Options Oncol. 2016; 17: 42.
6. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, et al. IDH1 and IDH2 Mutations in Gliomas. New England Journal of Medicine. 2009; 360: 765-73.
7. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science. 2009; 100: 1996-8.
8. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon R, Rasheed BA, et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science. 2008; 321: 1807-12.
9. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. American Association for Cancer Research. 2009; 15: 6002-7.
10. Cui D, Ren J, Shi J, Feng L, Wang K, Zeng T, Jin Y, Gao L. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/beta-catenin signaling. Int J Biochem Cell Biol. 2016; 73: 72-81.
11. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-8.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105: 10513-8.
13. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137: 1005-17.
14. Bertoli G, Cava C, Castiglioni I. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics. 2015; 5: 1122-43.
15. Li Y, Deng X, Zeng X, Peng X. The Role of Mir-148a in Cancer. J Cancer. 2016; 7: 1233-41.
16. Kim J, Zhang Y, Skalski M, Hayes J, Kefas B, Schiff D, Purow B, Parsons S, Lawler S, Abounader R. microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. Cancer Res. 2014; 74: 1541-53.
17. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 2011; 118: 449-57.
18. Hua D, Mo F, Ding D, Li L, Han X, Zhao N, Foltz G, Lin B, Lan Q, Huang Q. A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing. Omics. 2012; 16: 690-9.
19. Wang H, Pan JQ, Luo L, Ning XJ, Ye ZP, Yu Z, Li WS. NF-kappaB induces miR-148a to sustain TGF-beta/Smad signaling activation in glioblastoma. Mol Cancer. 2015; 14: 2.
20. Asuthkar S, Nalla AK, Gondi CS, Dinh DH, Gujrati M, Mohanam S, Rao JS. Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT. Neuro Oncol. 2011; 13: 1059-73.
21. Jin S, Antinore MJ, Lung FD, Dong X, Zhao H, Fan F, Colchagie AB, Blanck P, Roller PP, Fornace AJ, Jr., Zhan Q. The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem. 2000; 275: 16602-8.
22. Liebermann DA, Tront JS, Sha X, Mukherjee K, Mohamed-Hadley A, Hoffman B. Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog. 2011; 16: 129-40.
23. Salvador JM, Brown-Clay JD, Fornace AJ, Jr. Gadd45 in stress signaling, cell cycle control, and apoptosis. Adv Exp Med Biol. 2013; 793: 1-19.
24. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJ, Jr., Harris CC. GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A. 1999; 96: 3706-11.
25. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, Wu KC, Faull KF, Cloughesy T, et al. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol. 2013; 15: 57-68.
26. Fu Y, Zheng S, An N, Athanasopoulos T, Popplewell L, Liang A, Li K, Hu C, Zhu Y. β-catenin as a potential key target for tumor suppression. International Journal of Cancer. 2011; 129: 1541-51.
27. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells. American Association for Cancer Research. 2012; 10: 1597-606.
28. Anson M, Crain-Denoyelle A-M, Baud V, xE, ronique, Chereau F, Gougelet A, xE, lique, Terris B, Yamagoe S, Colnot S, Viguier M, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. The Journal of Clinical Investigation. 2012; 122: 586-99.
29. Zhang K, Zhu S, Liu Y, Dong X, Shi Z, Zhang A, Liu C, Chen L, Wei J, Pu P, Zhang J, Jiang T, Han L, et al. ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/β-catenin activity. Cancer Letters. 2015; 357: 404-11.
30. Liu X, Wang L, Zhao S, Ji X, Luo Y, Ling F. β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells. Medical Oncology. 2011; 28: 608-14.
31. Shi Z, Qian X, Li L, Zhang J, Zhu S, Zhu J, Chen L, Zhang K, Han L, Yu S, Pu P, Jiang T, Kang C. Nuclear Translocation of β-catenin is Essential for Glioma Cell Survival. Journal of Neuroimmune Pharmacology. 2012; 7: 892-903.
32. Ji J, Liu R, Tong T, Song Y, Jin S, Wu M, Zhan Q. Gadd45a regulates beta-catenin distribution and maintains cell-cell adhesion/contact. Oncogene. 2007; 26: 6396-405.
33. Yan H, Dong X, Zhong X, Ye J, Zhou Y, Yang X, Shen J, Zhang J. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog. 2014; 53: 960-9.
34. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS, Niederhuber J. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. 2013; 32: 3246-53.
35. Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, et al. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clin Cancer Res. 2014; 20: 5808-22.
36. Chen H, Li X, Li W, Zheng H. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase. J Transl Med. 2015; 13: 69.
37. Fu Y, Ong LC, Ranganath SH, Zheng L, Kee I, Zhan W, Yu S, Chow PK, Wang CH. A Dual Tracer 18F-FCH/18FFDG PET Imaging of an Orthotopic Brain Tumor Xenograft Model. PLoS One. 2016; 11: e0148123.
38. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005; 33: e179.
39. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008; 44: 619-26.
40. Lu C, Wang X, Zhu H, Feng J, Ni S, Huang J. Overexpression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6: 24912-21. doi: 10.18632/oncotarget.4701.
41. Zhu J, Ma J, Wang X, Ma T, Zhang S, Wang W, Zhou X, Shi J. High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer. Transl Oncol. 2016; 9: 592-9.
42. Sun R, Wang X, Zhu H, Mei H, Wang W, Zhang S, Huang J. Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues. Oncotarget. 2014; 5: 12398-409. doi: 10.18632/oncotarget.2643.
43. Uno M, Oba-Shinjo SM, Silva R, Miura F, Clara CA, Almeida JR, Malheiros SM, Bianco AM, Brandt R, Ribas GC, Feres H, Dzik C, Rosemberg S, et al. IDH1 mutations in a Brazilian series of Glioblastoma. Clinics (Sao Paulo). 2011; 66: 163-5.
44. da Ros M, Iorio AL, Consolante D, Cardile F, Muratori M, Fantappie O, Lucchesi M, Guidi M, Pisano C, Sardi I. Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastoma. Am J Cancer Res. 2016; 6: 639-48.